Axogen, Inc. To Host Analyst & Investor Day on March 4th
Rhea-AI Summary
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, has announced its upcoming Analyst & Investor Day scheduled for March 4, 2025, from 9am to 12pm Eastern time.
The event will feature presentations from key leadership including Chief Executive Officer Michael Dale, Chief Financial Officer Nir Naor, and other senior team members. Attendees can expect comprehensive insights into Axogen's business overview, strategic initiatives, growth plans, financial results, and future objectives.
For those unable to attend in person, a live webcast will be available on Axogen's investor relations website under "Axogen Virtual Analyst & Investor Day." A replay of the webcast will remain accessible for 90 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, AXGN gained 11.66%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, will hold its Analyst & Investor Day on March 4, 2025, between 9am-12pm Eastern.
Featured speakers will include Chief Executive Officer - Michael Dale, Chief Financial Officer - Nir Naor, and other senior members of the leadership team. During the event, the Axogen team will offer an overview of the business, strategic initiatives and growth plans, and discuss financial results and objectives.
A live webcast of the event will also be available and can be viewed on Axogen’s investor relations website under Axogen Virtual Analyst & Investor Day. After the event, a replay of the webcast will be available for 90 days in the same location.
About Axogen
Axogen (AXGN) is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products that are used across two primary application categories: scheduled, non-trauma procedures and emergent trauma procedures. Scheduled procedures are generally characterized as those where a patient is seeking relief from conditions caused by a nerve defect or surgical procedure. These procedures include providing sensation for women seeking breast reconstruction following a mastectomy, nerve reconstruction following the surgical removal of painful neuromas, oral and maxillofacial procedures, and nerve decompression. Emergent procedures are generally characterized as procedures resulting from injuries that initially present in an ER. These procedures are typically referred to and completed by a specialist either immediately or within a few days following the initial injury.
Axogen’s product portfolio includes Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine submucosa ECM coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard HA+ Nerve Protector™, a porcine submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to provide short- and long-term protection for peripheral nerve injuries; Avive+ Soft Tissue Matrix™, a multi-layer amniotic membrane allograft used to protect and separate tissues in the surgical bed during the critical phase of tissue repair; and Axoguard Nerve Cap®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
| Contact: Axogen, Inc. InvestorRelations@axogeninc.com |
FAQ
When is Axogen's (AXGN) Analyst & Investor Day in 2025?
Who will be speaking at AXGN's upcoming Investor Day?
How can investors access Axogen's (AXGN) March 2025 Investor Day remotely?
What topics will be covered during AXGN's March 4th Investor Day?
How long will the replay of AXGN's Investor Day be available?
